Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Nemolizumab Humanized Recombinant Human Monoclonal Antibody
Human Recombinant Monoclonal Antibody
Supplier: Invitrogen™ MA542056
This item is not returnable.
View return policy
Description
Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
Nemolizumab is a biosimilar that targets IL31RA. IL-31 is a T cell cytokine that is preferentially produced by T helper type 2 cells. IL-31 signals through a heterodimeric receptor composed of the IL-31 receptor (IL-31R) and the oncostatin M receptor (OSM). This receptor complex recruits JAK1, JAK2, Stat1, Stat3 and Stat5 signaling pathways, as well as the pi3 kinase/AKT cascade. SHP-2 and Shc adapter molecules are also recruited and contribute to an increased activation of the MAP kinase pathway in response to IL-31. Overexpression of IL-31 in mice results in pruritus and skin dermatitis resembling human atopic dermatitis (AD). Comparisons between skin from patients with AD and healthy skin showed IL-31R expression at higher levels on epidermal keratinocytes in AD samples. Infiltrating cells, more numerous in skin from patients with AD compared with that of healthy individuals, expressed IL-31 mRNA. IL-31 may participate in the cause of itch sensation and promote scratching behavior in NC/Nga mice with atopic dermatitis, and may represent a novel target for antipruritic drug development.
Specifications
Nemolizumab Humanized | |
Recombinant Monoclonal | |
Unconjugated | |
CIM 331 | |
Human IL31RA. | |
100 μg | |
Primary | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid | |
Chemical |
ELISA | |
2.5 mg/mL | |
PBS with no preservative; pH 7.4 | |
Human | |
Protein A/G | |
RUO | |
Human | |
Antibody | |
IgG2 κ |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction